In our study, following univariate analysis, patients that were in treatment with mTOR had a higher rate of HCC recurrence (p = 0.03): However, we must consider that, in most cases, the switch of immunosuppression to mTOR was made after the diagnosis of post-LT HCC recurrence. This evidence concerns the gene MTOR and hepatocellular carcinoma.